Dental News - Salvin announces the acquisition of Exactech’s dental biologics assets

Search Dental Tribune

Salvin announces the acquisition of Exactech’s dental biologics assets

Thu. 14 April 2016

save

Salvin Dental Specialties, through its Salvin Regenerative subsidiary, recently announced that it has acquired substantially all of the assets of Exactech’s dental biologics business. Salvin Dental Specialties, a privately held company doing business in more than 100 countries, develops, manufactures and markets regenerative biomaterials and surgical instrumentation specifically for implant dentistry.

According to founder and CEO Bob Salvin, Exactech has an exciting dental product line, and this acquisition will provide Salvin with greater product depth as well as additional manufacturing capabilities.

Exactech is a publicly traded company that develops and produces bone and joint restoration products for hip, knee, shoulder and spine.

Exactech’s Dental Biologics Division supplies the dental market with dental biologic products, including Optecure and Oralife. Optecure Dental is an engineered bone graft for reconstruction and augmentation of deficient maxillary and mandibular alveolar ridges and dental intraosseous defects.

Exactech Senior Vice President and General Manager of Spine and Biologics Bruce Thompson said, “We have made the strategic decision to focus more exclusively on our core orthopaedic business, and our long-standing distribution relationship with Salvin gives us confidence that it will take good care of dental customers in their pursuit of improving patient care.”

Financial terms were not disclosed. Deloitte Corporate Finance acted as an advisor to Salvin Dental.

(Source: Salvin Dental Specialties)

 

To post a reply please login or register
advertisement
advertisement